

[x](#)

## How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
  - For example, a search on Aminosalicyclic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
  - A search for “Aminosalicyclic Acid Tablets” will result in anything that specifically contains “Aminosalicyclic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
  - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:** You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

<a href="#">Monograph Title</a> <a href="#">Section</a>	<a href="#">Source</a> <a href="#">Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post</a> <a href="#">Date</a> <a href="#">Sort</a> <a href="#">ascending</a>	<a href="#">Errata Official</a> <a href="#">Date</a>	<a href="#">Target Errata</a> <a href="#">Print Publication</a>	<a href="#">Target Online</a> <a href="#">Fix Publication</a>	Description
PETROLATUM IM	USP37–NF32	4253	21-Nov-2014	1-Dec-2014	USP39–NF34	Second	Line 1 of

<a href="#">Monograph Title</a>	<a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a>	<a href="#">Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
	PUR ITIES/ <i>Organic Impurities/Procedure: Organic Acids</i>							<i>Supplement to USP38–NF33</i>	<i>Sample solution: Change 20.0 g of Petrolatum in 100 mL of neutralized alcohol and water (1:2). to: 20.0 g of Petrolatum in 100 mL of a 1 in 2 mixture of neutralized alcohol and water.</i>
SULFAMETHO XAZOLE AND RIMETHOPRIM ORAL SUSPENSION	ASSAY/ <i>Procedure</i>	USP37–NF32	4785	21-Nov-2014		1-Dec-2014	USP39–NF34	<i>Second Supplement to USP38–NF33</i>	Line 3 of <i>Standard solution: Change in Mobile phase from Sample stock solution to: in Mobile phase from Standard stock solution</i>
TRIBASIC CALCIUM	ASSAY/ <i>Procedure</i>	USP37–NF32	5883	21-Nov-2014		1-Dec-2014	USP39–NF34	<i>Second Supplement to</i>	Delete the subsection

<a href="#">Monograph Title</a>	<a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a>	<a href="#">Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
PHOSPHATE								USP38–NF33	Blank: Proceed as directed in the <i>Analysis</i> , omitting the test specimen. AND Equation in <i>Analysis</i> : Change Result = $\{ [V_S ? V_B) \times M \times F] / W \} \times 100$ to: Result = $[(V_S \times M \times F) / W] \times 100$ AND Line 2 of the variable definition list in <i>Analysis</i> : Delete $V_B = \textit{Titrant}$ volume consumed by the <i>Blank</i> (mL)
TRAZODONE HYDROCHLORIDE	IM PURITIES/ Limit Supplement to of Trazodone Related Compound F and Cyclophosp amide Related	First USP37–NF32	6708	21-Nov-2014		1-Dec-2014	USP39–NF34	Second Supplement to USP38–NF33	Line 4 of <i>Acquisition mode</i> : Change 272 to: 273

<a href="#">Monograph Title</a>	<a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
				<a href="#">Sort ascending</a>				
	<i>Compound A/ Chromatographic system/MS conditions</i>							
MEBENDAZOLE	ASSAY/ Procedure	<i>Second Supplement to USP37–NF32</i>	7199	21-Nov-2014	1-Dec-2014	<i>USP39–NF34</i>	<i>Second Supplement to USP38–NF33</i>	Line 3 of Analysis: Change Calculate the percentage of each impurity in the portion of Oral Suspension taken: to: Calculate the percentage of mebendazole (C <sub>16</sub> H <sub>13</sub> N <sub>3</sub> O <sub>3</sub> ) in the portion of Mebendazole taken:
DOLASETRON MESYLATE	CHEMICAL INFORMATION	<i>USP37–NF32</i>	2693	21-Nov-2014	1-Dec-2014	<i>USP39–NF34</i>	<i>Second Supplement to USP38–NF33</i>	Line 7: Change [115956-13-3]. to: [878143-33-0] Anhydrous [115956-13-3].
FENTANYL	ADDITIONAL REQUIREMENT	<i>Second Supplement to</i>	Online	21-Nov-2014	1-Dec-2014	<i>USP39–NF34</i>	<i>Second Supplement to</i>	Delete USP Fentanyl

<a href="#">Monograph Title</a> <a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a> <a href="#">Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
S/USP Reference Standards <11>	USP37–NF32					USP38–NF33	Related Compound C RS AND Delete USP Fentanyl Related Compound F RS
METFORMIN H PERFORMANC YDROCHLORI E DE EXTENDED-TESTS/ RELEASE TABLETS	<i>Dissolution</i> <711>	USP37–NF32 3732	21-Nov-2014	1-Dec-2014	USP39–NF34	<i>Second Supplement to USP38–NF33</i>	Equation in <i>Test 1</i> : Change Result = $[(A_U/A_S) \times C_S \times (V ? V_S) + (C_{60} \times V_S) + (C_{180} \times V_S) \times 100]/L$ to: Result = $[(A_U/A_S) \times C_S \times (V ? V_S) + (C_{60} \times V_S) + (C_{180} \times V_S)] \times (100/L)$ AND Equation 3 in <i>Test 2</i> : Change Result = $[C_2 \times (V ? SV_1) + C_1 \times SV_1 \times 100]/L$ to: Result = $[C_2 \times (V ? SV$

<a href="#">Monograph Title</a>	<a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a>	<a href="#">Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
									$1) + C_1 \times SV_1] \times (100/L)$ AND Equation 4 in <i>Test 2</i> : Change Result = $\{C_n \times [V$ $? (n ? 1) V_S] +$ $(C_1 + C_2 + \dots +$ $C_{n-1}) \times V_S$ $\times 100\}/L$ to: Result = $\{C_n \times [V$ $? (n ? 1) V_S] +$ $(C_1 + C_2 + \dots +$ $C_{n-1}) \times V_S\}$ $\times (100/L)$
SACCHARIN SODIUM	IM PUR ITIES/ <i>Organic Impurities/Procedure 1: Limit of Toluene sulfonamides</i>	USP37–NF32	4638	21-Nov-2014		1-Dec-2014	USP39–NF34	<i>Second Supplement to USP38–NF33</i>	Line 4 of <i>Acceptance criteria</i> : Change of the <i>Internal standard solution</i> to: of the caffeine (internal standard)
ZANAMIVIR	IM PUR ITIES/ <i>Organic Impurities/</i>	USP37–NF32	5197	21-Nov-2014		1-Dec-2014	USP39–NF34	<i>Second Supplement to USP38–NF33</i>	Line 1 of <i>Column</i> : Change 5-?m packing L## <sup>1</sup>

<a href="#">Monograph Title</a>	<a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a>	<a href="#">Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
		<i>Chromatographic system</i>							to: 5-?m packing L82
CHLORPHENIRAMINE MALEATE	SPECIFIC TESTS/Optical Rotation, Specific Rotation <781>	<i>First Supplement to USP37–NF32</i>	6617	21-Nov-2014		1-Dec-2014	<i>USP39–NF34</i>	<i>Second Supplement to USP38–NF33</i>	Line 1 of <i>Sample:</i> Change 100 mg/mL in water to: 100 mg/mL in water at 20°
HYDROXYPROPYL CELLULOSE	ASSAY	<i>Second Supplement to USP37–NF32</i>	7080	21-Nov-2014		1-Dec-2014	<i>USP39–NF34</i>	<i>Second Supplement to USP38–NF33</i>	Line 1 of <i>Internal standard solution:</i> Change Methylcyclohexane to: Methylcyclohexane
CEFADROXIL FOR ORAL SUSPENSION	IDENTIFICATION/ <i>Thin-Layer Chromatographic system</i>	<i>USP37–NF32</i>	2182	21-Nov-2014		1-Dec-2014	<i>USP39–NF34</i>	<i>Second Supplement to USP38–NF33</i>	Line 2 of <i>Developing solvent system:</i> Change (60:40:15) to: (60: 40: 1.5)
GANODERMALUCIDUM	SPECIFIC TESTS/	<i>Revision Bulletin (Official</i>	Online	21-Nov-2014		1-Dec-2014	<i>USP39–NF34</i>	<i>Second Supplement to</i>	Line 6 of <i>Macroscopic:</i>

<a href="#">Monograph Title</a>	<a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a>	<a href="#">Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
FRUITING BODY		<i>Botanical Characteristics</i>						USP38–NF33	Change concentrically culcate to: concentrically sulcate
LAMIVUDINE AND ZIDOVUDINE TABLETS	IM PURITIES/ <i>Organic Impurities</i>	USP37–NF32	3484	21-Nov-2014		1-Dec-2014	USP39–NF34	<i>Second Supplement to USP38–NF33</i>	Row 17 of Column 1 of Table 2: Change (the limit includes individual unidentified impurities) to: (the limit includes individual unspecified impurities)
WHITE PETROLATUM	IM PURITIES/ <i>Organic Impurities/Procedure: Organic Acids</i>	USP37–NF32	4254	21-Nov-2014		1-Dec-2014	USP39–NF34	<i>Second Supplement to USP38–NF33</i>	Line 1 of Sample solution: Change 20.0 g in 100 mL of neutralized alcohol and water (1:2). to:



<a href="#">Monograph Title</a>	<a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a>	<a href="#">Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
SULFAMETHO XAZOLE AND T RIMETHOPRIM TABLETS	ASSAY/ <i>Procedure</i>	USP37–NF32	4787	21-Nov-2014		1-Dec-2014	USP39–NF34	<i>Second Supplement to USP38–NF33</i>	20.0 g of White Petrolatum in 100 mL of a 1 in 2 mixture of neutralized alcohol and water. Line 3 of <i>Standard solution</i> : Change in <i>Mobile phase</i> from <i>Sample stock solution</i> to: in <i>Mobile phase</i> from <i>Standard stock solution</i>
TRIBASIC CALCIUM PHOSPHATE	IM PUR ITIES/ <i>Dibasic Salt and Calcium Oxide</i>	USP37–NF32	5883	21-Nov-2014		1-Dec-2014	USP39–NF34	<i>Second Supplement to USP38–NF33</i>	Delete the subsection <i>Blank</i> : 25.0 mL of <i>Titrant</i>
TRAZODONE HYDROCHLOR IDE	ADDITIONAL R EQUIREMENT S/ <i>USP Reference Standards &lt;11&gt;</i>	<i>First Supplement to USP37–NF32</i>	6708	21-Nov-2014		1-Dec-2014	USP39–NF34	<i>Second Supplement to USP38–NF33</i>	Line 2 of USP Trazodone Related Compound D RS: Change (2-{3-[4-(4-Bromophenyl)piperaz

<a href="#">Monograph Title</a>	<a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a>	<a href="#">Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
									in-1-yl]propyl}-[1
									? ]pyri din-3(2 <i>H</i> )-one hydrochloride. to: 2-{3-[4-(3-Brom ophenyl)piperaz in-1-yl]propyl}-[1
									? ]pyri din-3(2 <i>H</i> )-one hydrochloride. Line 1 of <i>Single- Dose</i> (see also <i>Injections</i> <1>, <i>Containers</i> <i>for Injections</i> ): Change A single-unit package for an article intended for parenteral administration. Examples of
PACKAGING AND STORAGE RE QUIREMENTS	GENERAL DEFINITIONS	<i>USP37–NF32</i>	315	21-Nov-2014		1-Dec-2014	<i>USP39–NF34</i>	<i>Second Supplement to USP38–NF33</i>	

<a href="#">Monograph Title</a> <a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a> <a href="#">Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
							<p>single-dose containers include prefilled syringes, cartridges, fusion-sealed containers, and closure-sealed containers when so labeled.</p> <p>to:</p> <p>A single-unit package for an article intended for parenteral administration. A single-dose container is labeled as such. Examples of single-dose containers include prefilled syringes, cartridges, fusion-sealed containers, and closure-sealed containers when so</p>

<a href="#">Monograph Title</a>	<a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a>	<a href="#">Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
SODIUM PICOSULFATE	CHEMICAL INFORMATION	<i>Second Supplement to USP37–NF32</i>	7253	21-Nov-2014		1-Dec-2014	<i>USP39–NF34</i>	<i>Second Supplement to USP38–NF33</i>	labeled. Line 5: Change Disodium 4,4?-(pyridin-2-ylmethanediyl)dibenzenesulfonate to: Disodium 4,4?-(pyridin-2-ylmethanediyl)dibzenesulfate
FLUDARABINE IM PHOSPHATE		<i>USP37–NF32</i>	3003	21-Nov-2014		1-Dec-2014	<i>USP39–NF34</i>	<i>Second Supplement to USP38–NF33</i>	Line 1 of <i>Standard solution</i> : Change 1 µg/mL of sodium chloride in water to: 1 µg/mL of sodium in water
NIFEDIPINE EXTENDED-RELEASE TABLETS	PERFORMANCE TESTS/ <i>Dissolution &lt;711&gt;/Test 2</i>	<i>Second Supplement to USP37–NF32</i>	Online	21-Nov-2014		1-Dec-2014	<i>USP38–NF33</i>	<i>USP38–NF33</i>	Line 1 of <i>Solution A</i> : Change sodium phosphate to: dibasic sodium phosphate
MINOCYCLINE FOR	IMPURITIES	<i>USP37–NF32</i>	3843	21-Nov-2014		1-Dec-2014	<i>USP39–NF34</i>	<i>Second Supplement to</i>	Line 6 of <i>Limit of</i>

<a href="#">Monograph Title</a> <a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a> <a href="#">Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
INJECTION						<i>USP38–NF33</i>	<i>Epiminocycline: Change [Note—The relative retention times for epiminocycline and minocycline are 0.86 and 1.0, respectively.] to: [Note—The relative retention times for epiminocycline and minocycline are 0.7 and 1.0, respectively.]</i>
SULFAMETHO ASSAY/ XAZOLE AND T RIMETHOPRIM INJECTION	<i>USP37–NF32</i>	4784	21-Nov-2014	1-Dec-2014	<i>USP39–NF34</i>	<i>Second Supplement to USP38–NF33</i>	<i>Line 3 of Standard solution: Change in Mobile phase from Sample stock solution to: in Mobile phase from Standard stock</i>

<a href="#">Monograph Title</a>	<a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
SAW PALMETTO EXTRACT	COMPOSITION <i>/Content of Long-Chain Alcohols and Sterols</i>	USP37–NF32	5545	21-Nov-2014	1-Dec-2014	USP39–NF34	Second Supplement to USP38–NF33	<i>solution</i> Line 3 of <i>Acceptance criteria</i> : Add The lipophilic Extract contains 0.15%–0.35% of long-chain alcohols, and the hydroalcoholic Extract contains 0.01%–0.15% of long-chain alcohols on the anhydrous basis.
ERYTHROMYCIN DELAYED-RELEASE TABLETS	PERFORMANCE TESTS/ <i>Dissolution &lt;711&gt;/Test 1/Buffer stage</i>	First Supplement to USP37–NF32	6633	21-Nov-2014	1-Dec-2014	USP39–NF34	Second Supplement to USP38–NF33	Line 1 of <i>Standard solution</i> : Change 0.28 mg/mL of USP Erythromycin RS in <i>Medium</i> to: Dissolve USP Erythromycin RS in <i>Medium</i> to obtain a concentration

<a href="#">Monograph Title</a>	<a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a>	<a href="#">Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
POLYSORBAT E 80	SPECIFIC TESTS/ <i>Fats and Fixed Oils, Acid Value</i> <401>	<i>Second Supplement to USP37–NF32</i>	7089	21-Nov-2014		1-Dec-2014	<i>USP39–NF34</i>	<i>Second Supplement to USP38–NF33</i>	<p>similar to that of the <i>Sample solution</i>.  AND  Line 1 of <i>Sample solution</i>:  Change  Pass portions of the solution under test through a suitable filter.  to:  If necessary, dilute a filtered portion of the solution under test with <i>Medium</i> to obtain a solution containing about 0.28 mg/mL of erythromycin.  Line 1 of <i>Analysis</i>:  Change with 0.1 N potassium</p>

<a href="#">Monograph Title</a>	<a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a>	<a href="#">Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
ESCITALOPRAM ORAL SOLUTION	IMPURITIES/ <i>Organic Impurities</i>	USP37–NF32	2580	26-Sep-2014		1-Oct-2014	USP39–NF34	First Supplement to USP38–NF33	hydroxide or 0.1 N sodium hydroxide to: with 0.1 N potassium hydroxide VS or 0.1 N sodium hydroxide VS Row 6 of Column 1 of Table 3: Change Desfluorocitalopram <sup>f</sup> to: Desfluorocitalopram <sup>f,c</sup>
KETOPROFEN EXTENDED-RELEASE CAPSULES	PERFORMANCE TESTS/ <i>Uniformity of Dosage Units &lt;905&gt;/System suitability/Suitability requirements</i>	USP37–NF32	3469	26-Sep-2014		1-Oct-2014	USP39–NF34	First Supplement to USP38–NF33	Line 1 of <i>Tailing factor</i> : Change NLT 1.5 to: NMT 1.5
STERILE WATER FOR INHALATION	CHEMICAL INFORMATION	USP37–NF32	5174	26-Sep-2014		1-Oct-2014	USP39–NF34	First Supplement to USP38–NF33	Add the chemical formula and molecular



<a href="#">Monograph Title</a>	<a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a>	<a href="#">Errata Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
STERILE WATER FOR IRRIGATION	ADDITIONAL REQUIREMENT S/USP Reference Standards <11>	USP37–NF32	5175	26-Sep-2014		1-Oct-2014	USP39–NF34	First Supplement to USP38–NF33	weight: H <sub>2</sub> O 18.02 Add: USP 1,4-Benzoquinone RS AND USP Sucrose RS
ETHYLCELLULOSE DISPERSION TYPE B	ASSAY/ Procedure	USP37–NF32	5981	26-Sep-2014		1-Oct-2014	USP39–NF34	First Supplement to USP38–NF33	Line 3 of Analysis: Change Calculate the percentage of ethylcellulose in the portion of Ethylcellulose Dispersion Type B taken: to: Calculate the percentage of the labeled amount of ethylcellulose in the portion of Ethylcellulose Dispersion Type B taken:
CALCIUM GLUCONATE INJECTION	Identification	USP37–NF32	2089	26-Sep-2014		1-Oct-2014	USP39–NF34	First Supplement to USP38–NF33	Line 1 of Identification test A: Change

<a href="#">Monograph Title</a> <a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a> <a href="#">Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
							<p>A volume of Injection diluted, if necessary, with water to obtain a test solution of calcium gluconate (1 in 100) responds to Identification test <i>B</i> under <i>Calcium Gluconate</i>.</p> <p>to:</p> <p>Dissolve a quantity of it in water to obtain a test solution containing 10 mg per mL, heating in a water bath at 60° if necessary. Similarly, prepare a Standard solution of USP Potassium Gluconate RS in water</p>

<a href="#">Monograph Title</a> <a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a> <a href="#">Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
							<p>containing 10 mg per mL. Apply separate 5-<math>\mu</math>L portions of the test solution and the Standard solution to a suitable thin-layer chromatographic plate (see <i>Chromatography</i> &lt;621&gt;) coated with a 0.25-mm layer of chromatographic silica gel, and allow to dry. Develop the chromatogram in a solvent system consisting of a mixture of alcohol, water, ammonium hydroxide, and ethyl acetate (50: 30: 10: 10) until the solvent front has moved</p>

<a href="#">Monograph Title</a> <a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a> <a href="#">Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
							about three-fourths of the length of the plate. Remove the plate from the chamber, and dry at 110° for 20 minutes. Allow to cool, spray with a spray reagent prepared as follows. Dissolve 2.5 g of ammonium molybdate in about 50 mL of 2 N sulfuric acid in a 100-mL volumetric flask, add 1.0 g of ceric sulfate, swirl to dissolve, dilute with 2 N sulfuric acid to volume, and mix. Heat the plate at 110° for about 10 minutes: the principal spot

<a href="#">Monograph Title</a> <a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a> <a href="#">Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
IRINOTECAN HIM YDROCHLORI PUR DE INJECTION ITIES/ <i>Organic Impurities</i>	USP37–NF32	3403	26-Sep-2014	1-Oct-2014	USP39–NF34	First Supplement to USP38–NF33	<p>obtained from the test solution corresponds in color, size, and <math>R_F</math> value to that obtained from the Standard solution.</p> <p>Row 3 of Column 1 of Table 2: Change Camptothecin<sup>b</sup> to:</p> <p>Camptothecin<sup>b,d</sup> AND Row 5 of Column 1: Change 7-Ethylcamptothecin<sup>c</sup> to: 7-Ethylcamptothecin<sup>c,d</sup> AND Add a footnote: <sup>d</sup>These process impurities are included in the table for</p>

<a href="#">Monograph Title</a>	<a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a>	<a href="#">Errata Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
WATER FOR H CHEMICAL EMODIALYSIS INFORMATION		USP37–NF32	5173	26-Sep-2014		1-Oct-2014	USP39–NF34	First Supplement to USP38–NF33	identification only and are not included in the <i>Total impurities</i> . Add the chemical formula and molecular weight: H <sub>2</sub> O 18.02
STERILE WATER FOR INJECTION	ADDITIONAL REQUIREMENT S/USP Reference Standards <11>	USP37–NF32	5175	26-Sep-2014		1-Oct-2014	USP39–NF34	First Supplement to USP38–NF33	Add: USP 1,4-Benzoquinone RS AND USP Sucrose RS
CELLACEFATE ASSAY/Content of Acetyl		USP37–NF32	5919	26-Sep-2014		1-Oct-2014	USP39–NF34	First Supplement to USP38–NF33	Line 12 of <i>Analysis</i> : Result = $\frac{[(P \times 0.5182 \times B) / (100 \times B)] \times (0.5772 \times C)}{100}$ to: Result = $100 \times \frac{[P \times (0.5182 \times B) / (100 \times B)] \times (0.5772 \times C)}{100}$
DACARBAZINE IM FOR INJECTION	PURITIES/Limit of 2-Azahypoxa	Second Supplement to USP37–NF32	Online	26-Sep-2014		1-Oct-2014	USP39–NF34	First Supplement to USP38–NF33	Line 2 of <i>Analysis</i> : Change

<a href="#">Monograph Title</a> <a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a> <a href="#">Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
							2-azahypoxanthine monohydrate to: 2-azahypoxanthine
DIDANOSINE DPERFORMANC ELAYED- RELEASE CAPSULES	E TESTS/ <i>Dissolution</i> <711>/ <i>Analysis</i>	USP37–NF32 2603	26-Sep-2014	1-Oct-2014	USP39–NF34	<i>First Supplement to USP38–NF33</i>	Line 11 of the variable definition list: Change $C_S =$ concentration of didanosine in the <i>Standard solution</i> (mg/mL) to: $C_S =$ concentration of USP Didanosine Related Compound A RS in the <i>Standard solution</i> for the <i>Acid stage</i> or concentration of USP Didanosine RS in the <i>Standard</i>

<a href="#">Monograph Title</a>	<a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a>	<a href="#">Errata Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
OXYBUTYNIN CHLORIDE	SPECIFIC TESTS/ <i>Loss on Drying</i> <731>	USP37–NF32	4129	26-Sep-2014		1-Oct-2014	USP39–NF34	First Supplement to USP38–NF33	<i>solution for the Buffer stage</i> (mg/mL) Line 1 of <i>Acceptance criteria</i> : Change NMT 3.0% to: NMT 3% Add: USP 1,4-Benzoquinone RS AND USP Sucrose RS
STERILE WATER FOR INHALATION	ADDITIONAL REQUIREMENT S/USP <i>Reference Standards</i> <11>	USP37–NF32	5174	26-Sep-2014		1-Oct-2014	USP39–NF34	First Supplement to USP38–NF33	Add the chemical formula and molecular weight: H <sub>2</sub> O 18.02
PURE STEAM	CHEMICAL INFORMATION	USP37–NF32	5176	26-Sep-2014		1-Oct-2014	USP39–NF34	First Supplement to USP38–NF33	Add the chemical formula and molecular weight: H <sub>2</sub> O 18.02
CHLORPHENIRAMINE MALEATE	IMPURITIES/ <i>Organic Impurities</i>	First Supplement to USP37–NF32	6617	26-Sep-2014		1-Oct-2014	USP39–NF34	First Supplement to USP38–NF33	Line 1 of <i>Standard solution</i> : Change 1.1 ?g/mL of USP Chlorpheniramine Maleate RS in <i>Diluent</i> , to:



<a href="#">Monograph Title</a> <a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a> <a href="#">Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description	
DACARBAZINE USP Reference standards <11>	USP37–NF32	2504	26-Sep-2014	1-Oct-2014	USP39–NF34	First Supplement to USP38–NF33	1.4 ?g/mL of USP Chlorpheniramine Maleate RS in <i>Diluent</i> , Line 3 of USP Dacarbazine Related Compound B RS: Change C <sub>4</sub> H <sub>3</sub> N <sub>5</sub> O 137.10 to: C <sub>4</sub> H <sub>3</sub> N <sub>5</sub> O · H <sub>2</sub> O 155.12	
KETOPROFEN ASSAY/ EXTENDED-RELEASE CAPSULES	USP37–NF32	3469	26-Sep-2014	1-Oct-2014	USP39–NF34	First Supplement to USP38–NF33	Line 1 of <i>Tailing factor</i> : Change NLT 1.5 to: NMT 1.5	
WATER FOR INJECTION	CHEMICAL INFORMATION	USP37–NF32	5173	26-Sep-2014	1-Oct-2014	USP39–NF34	First Supplement to USP38–NF33	Add the chemical formula and molecular weight: H <sub>2</sub> O 18.02
STERILE WATER FOR IRRIGATION	CHEMICAL INFORMATION	USP37–NF32	5175	26-Sep-2014	1-Oct-2014	USP39–NF34	First Supplement to USP38–NF33	Add the chemical formula and molecular weight:

<a href="#">Monograph Title</a>	<a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a>	<a href="#">Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
POWDERED CELLULOSE	IDENTIFICATION N/B. Procedure	USP37–NF32	5923	26-Sep-2014		1-Oct-2014	USP39–NF34	First Supplement to USP38–NF33	H <sub>2</sub> O 18.02 Fourth equation in Analysis: Change Result = $95 \times \frac{[?]}{W_s} \times \frac{[(100 - ? \% \text{LOD})]}{100}$ to: Result = $[95 \times \frac{[?]}{W_s} \times \frac{[(100 - ? \% \text{LOD})]}{100}]$
BETAMETHASONE SODIUM PHOSPHATE	IM PURITIES/Limit of Free Betamethasone	USP37–NF32	1965	26-Sep-2014		1-Oct-2014	USP39–NF34	First Supplement to USP38–NF33	Line 1 of Sample stock solution: Change 1.0 mg/mL of Betamethasone Sodium Phosphate in water to: 1.0 mg/mL of Betamethasone Sodium Phosphate in water, prepared as follows. Dissolve 25.0 mg of Betamethasone Sodium

---

<a href="#">Monograph Title</a> <a href="#">Section</a>	<a href="#">Source Publication</a>	<a href="#">Page Number</a>	<a href="#">Errata Post Date</a> <a href="#">Sort ascending</a>	<a href="#">Errata Official Date</a>	<a href="#">Target Errata Print Publication</a>	<a href="#">Target Online Fix Publication</a>	Description
							Phosphate in water to make 25.0 mL.

## Pagination

- [First page « First](#)
- [Previous page ‹ Previous](#)
- ...
- [Page 27](#)
- [Page 28](#)
- [Page 29](#)
- [Page 30](#)
- [Page 31](#)
- [Page 32](#)
- [Page 33](#)
- [Page 34](#)
- [Page 35](#)
- ...
- [Next page Next ›](#)
- [Last page Last »](#)